Pre-Eclampsia - Pipeline Insight, 2024

This “Pre-Eclampsia - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pre-Eclampsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pre-Eclampsia: Understanding

Pre-Eclampsia: Overview

Pre-Eclampsia is a hypertensive disorder that arises during pregnancy, typically identified by a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher, recorded on two occasions at least 4 hours apart. A more immediate diagnosis can be made if the systolic blood pressure reaches 160 mm Hg or more, or the diastolic pressure reaches 110 mm Hg or more, and these measurements must occur after 20 weeks of gestation. Pre-eclampsia generally presents in near-term pregnancies.

Abnormal placentation, which leads to significant abnormal remodeling of placental vessels, is central to the pathogenesis of pre-eclampsia. The condition progresses as vascular sclerosis and improper arteriole remodeling cause placental ischemia, resulting in the release of distress signals like antiangiogenic and pro-inflammatory factors. These factors disrupt the balance between angiogenic and essential growth factors by competing for binding sites, leading to abnormal vessel formation and insufficient vascular adaptation in multiple organ systems, particularly affecting the cardiovascular, renal, and hepatic systems. Pre-eclampsia is, therefore, a multisystem condition that can escalate to severe hypertension and organ dysfunction or failure.

Pre-eclampsia can develop for the first time during labor (intrapartum) or after delivery (postpartum). Superimposed pre-eclampsia is diagnosed when women with chronic hypertension develop new-onset proteinuria, maternal organ dysfunction, or uteroplacental dysfunction indicative of pre-eclampsia. Eclampsia, the progression of the condition, occurs when convulsions arise in the presence of pre-eclampsia. Proteinuria is traditionally screened via dipstick testing, with confirmation through additional laboratory tests like 24-hour urine collections or spot urine samples. Automated reagent-strip reading devices are preferred over visual analysis for dipstick testing.

The ISSHP (International Society for the Study of Hypertension in Pregnancy) advises that pregnant women with newly diagnosed hypertension undergo laboratory tests, including measurements of hemoglobin, platelet count, serum creatinine, liver enzymes, and serum uric acid. These tests help determine the presence of maternal organ dysfunction and confirm the diagnosis of pre-eclampsia. The only definitive treatment for pre-eclampsia is delivery, and determining the optimal timing requires balancing maternal and fetal risks, considering the gestational age of the fetus. Metformin has emerged as a potential treatment option in preeclampsia.

Preclinical studies using human tissue have shown that metformin can reduce the secretion of sFlt-1 and endoglin, improve endothelial function and angiogenesis, and enhance vasodilation. Given its established safety in pregnancy due to its use in diabetes, metformin is a promising option, though randomized controlled trials (RCTs) to evaluate its efficacy in pre-eclampsia are still needed. Plasma apheresis, aimed at removing the antiangiogenic protein sFlt-1, has also been explored as a treatment option.

"Pre-Eclampsia- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pre-Eclampsia pipeline landscape is provided which includes the disease overview and Pre-Eclampsia treatment guidelines. The assessment part of the report embraces, in depth Pre-Eclampsia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pre-Eclampsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pre-Eclampsia R&D. The therapies under development are focused on novel approaches to treat/improve Pre-Eclampsia.

Pre-Eclampsia Emerging Drugs Chapters

This segment of the Pre-Eclampsia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pre-Eclampsia Emerging Drugs

CBP-4888: Comanche Biopharma

CBP-4888 is a fixed-dose combination of two chemically-synthesized, lipid-conjugated small interfering ribonucleic acid (siRNAs) duplex oligonucleotides (siRNA-2283 and siRNA-2519). The investigational therapy is designed to decrease the production of soluble fms-like tyrosine kinase-1 (sFLT1) mRNA isoforms in the placenta. Currently, the drug is in the Phase I stage of its development for the treatment of Preeclampsia.

Pre-Eclampsia: Therapeutic Assessment

This segment of the report provides insights about the different Pre-Eclampsia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pre-Eclampsia

• There are approx. 5+ key companies which are developing the therapies for Pre-Eclampsia. The companies which have their Pre-Eclampsia drug candidates in the most advanced stage, i.e. Phase I include, Comanche Biopharma.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pre-Eclampsia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Pre-Eclampsia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pre-Eclampsia drugs.

Pre-Eclampsia Report Insights

• Pre-Eclampsia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pre-Eclampsia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pre-Eclampsia drugs?
• How many Pre-Eclampsia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pre-Eclampsia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pre-Eclampsia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pre-Eclampsia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gmax Biopharm
• Corion Biotech
• Comanche Biopharma

Key Products

• GMA-312
• CB-CHMF-11
• CBP-4888

This product will be delivered within 2 business days.